🇺🇸 Rituximab (R) in United States
7 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 7
Most-reported reactions
- Abscess Neck — 1 report (14.29%)
- Condition Aggravated — 1 report (14.29%)
- Diastolic Dysfunction — 1 report (14.29%)
- Ejection Fraction Decreased — 1 report (14.29%)
- Human Herpesvirus 8 Infection — 1 report (14.29%)
- Kaposi^S Sarcoma — 1 report (14.29%)
- Pleuritic Pain — 1 report (14.29%)
Rituximab (R) in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology, Immunology approved in United States
Frequently asked questions
Is Rituximab (R) approved in United States?
Rituximab (R) does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Rituximab (R) in United States?
National Cancer Institute (NCI) is the originator. The local marketing authorisation holder may differ — check the official source linked above.